Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 1932-1934, 2004; 10.1373/clinchem.2004.037143
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banin, S.
Right arrow Articles by Stanley, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banin, S.
Right arrow Articles by Stanley, C. J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Oak Ridge Conference
(Clinical Chemistry. 2004;50:1932-1934.)
© 2004 American Association for Clinical Chemistry, Inc.


Abstracts of Oak Ridge Posters

Demonstration of an Alternative Approach to Immuno-PCR

Sharon Banina, Stuart M. Wilson and Christopher J. Stanley

1 ISEAO Technologies, 2 Royal College Street, London, NW1 0NH, United Kingdom

aauthor for correspondence: fax 44-20-7691-2036, e-mail sharon.banin@microsens.co.uk

The first 20% of the full text of this article appears below.

There have been many reports describing the combination of immunoassay techniques and nucleic acid amplification using antibodies labeled directly with nucleic acids (the "direct" immuno-PCR approach) (1)(2)(3). The rationale behind immuno-PCR is to develop ultrahigh-sensitivity labels by exploiting the extremely high productivity of nucleic acid amplification techniques, coupled with highly sensitive approaches to detect the amplified material. Specific applications in which the use of ultrahigh-sensitivity immuno-PCR techniques have been proposed include prion protein detection, in which there is no nucleic acid associated with the infectious agent, and the detection of viral antigens in blood bank screening applications, in which there can be very little viral nucleic acid present at certain stages of the infection.

Although the principle of immuno-PCR has been demonstrated in various research applications, there are continuing concerns over both the technical difficulty of linking nucleic acids directly to antibodies (or "adapter" proteins such as streptavidin) and the substantial backgrounds that can be generated by nonspecific binding of the nucleic acid–antibody conjugates to solid phases (2)(4).

We have developed an alternative approach based on an "indirect" immuno-PCR technique that links ELISA techniques and PCR. Because this approach works in a completely different way to traditional immuno-PCR, it may circumvent some of the problems associated with the traditional approach. Here we present the proof of principle of our new approach.

We used a double stranded 5'-phosphorylated DNA (dsDNA) substrate for alkaline phosphatase (AP). Shown in Fig. 1A is a schematic of the principle of the enzyme assay method. The procedure takes advantage of the substrate specificity of {lambda} exonuclease for the 5'-phosphorylated form of dsDNA (5). In an immunometric assay, the AP in the antibody conjugate will remove the 5' phosphate groups, and . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.